γ-Phenyl-L-β-homophenylalanine hydrochloride
Need Assistance?
  • US & Canada:
    +
  • UK: +

γ-Phenyl-L-β-homophenylalanine hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
β−Amino acids
Catalog number
BAT-007547
CAS number
332062-03-0
Molecular Formula
C16H18ClNO2
Molecular Weight
291.78
γ-Phenyl-L-β-homophenylalanine hydrochloride
IUPAC Name
(3R)-3-amino-4-(4-phenylphenyl)butanoic acid;hydrochloride
Synonyms
H-Dph-(C#CH2)OH HCl; (R)-3-Amino-4,4-diphenylbutanoic acid hydrochloride; H-D-β-HoAla(4,4-Diphenyl)-OH HCl; (R)-4-([1,1'-Biphenyl]-4-yl)-3-aminobutanoic acid hydrochloride; (R)-3-Amino-4,4-diphenyl-butyric acid HCl; (3R)-3-amino-4-(4-phenylphenyl)butanoic acid hydrochloride
Related CAS
544455-93-8 (free base)
Appearance
Powder
Purity
97%
InChI
InChI=1S/C16H17NO2.ClH/c17-15(11-16(18)19)10-12-6-8-14(9-7-12)13-4-2-1-3-5-13;/h1-9,15H,10-11,17H2,(H,18,19);1H/t15-;/m1./s1
InChI Key
OBYYHHGRCZYCAA-XFULWGLBSA-N
Canonical SMILES
C1=CC=C(C=C1)C2=CC=C(C=C2)CC(CC(=O)O)N.Cl
1.UV-Responsive Supramolecular Vesicles with Double Hydrophobic Chains.
Zhang X1, Dai Y2, Chen X3, Zhuo R1. Macromol Rapid Commun. 2016 Apr 14. doi: 10.1002/marc.201600077. [Epub ahead of print]
In order to improve the stability of polymeric vesicles, supramolecular vesicles are developed via self-assembly of the inclusion of γ-cyclodextrin (γ-CD) and 1-pyrenemethyl palmitate (Py-pal). The inclusion has one hydrophilic head and double hydrophobic tails, which looks like the phospholipid. From the transmission electron microscopy (TEM) image, it can be observed that the average diameter of supramolecular vesicles is approximately 55 nm and there is a huge cavity in supramolecular vesicles. Due to the photo-breakable ester of Py-pal, supramolecular vesicles are broken under UV irradiation. Supramolecular vesicles are used as UV-responsive drug carriers to release the hydrophilic drug such as doxorubicin hydrochloride (DOX•HCl).
2.Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K1, Sammons H1, Star K2, Ralph Edwards I2, Osakwe A3, Choonara I1. Paediatr Int Child Health. 2016 Jan 29:1-5. [Epub ahead of print]
BACKGROUND: Adverse drug reactions (ADRs) in children recorded in national pharmacovigilance databases in high-income countries have been analysed. Nigeria has a population of 31 million children and became a member of the WHO Programme for International Drug Monitoring in 2004 since when it has been submitting reports of suspected ADRs to the WHO Global Individual Case Safety Report database, VigiBase.
3.Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response.
Siproudhis L1, Graf W2, Emmanuel A3, Walker D4, Shing RN5, Pediconi C5, Pilot J5, Wexner S6, Scholefield J7. Int J Colorectal Dis. 2016 Apr 13. [Epub ahead of print]
PURPOSE: Faecal incontinence (FI) is distressing, significantly reduces quality of life (QoL) and has few pharmacological treatments. The α1-adrenoceptor agonist NRL001 (1R,2S-methoxamine hydrochloride) improves anal sphincter tone. NRL001 efficacy was evaluated by changes in Wexner scores at week 4 vs. baseline in NRL001-treated patients compared with placebo. Impact of NRL001 on QoL and safety were also assessed.
4.[The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
Mukhin NA1, Milovanov YS1, Kozlovskaya LV1, Dobrosmyslov IA1, Milovanova LY1. Ter Arkh. 2016;88(4):41-45.
in English, RussianРеферат Цель исследования. Изучить возможность снижения избыточной продукции фактора роста фибробластов 23-го типа (FGF-23) в сыворотке крови у больных хронической болезнью почек (ХБП) VD стадии путем воздействия на гиперфосфатемию связывающими фосфат препаратами. Материалы и методы. В исследование включили 25 пациентов с ХБП VD стадии, находящихся на регулярном гемодиализе (ГД), 12 — хроническим гломерулонефритом, 8 — тубулоинтерстициальным нефритом и 5 — гипертензивным нефросклерозом; среди них 15 мужчин и 10 женщин в возрасте от 21 года до 65 лет, средний возраст на момент включения в исследование 43±4,5 года. Проводили клиническое, лабораторное и инструментальное обследование, аналогичное таковому у больных с более ранними стадиями ХБП. У всех 25 больных изучен уровень FGF-23 в сыворотке крови (Human FGF-23 ELISA kit с использованием моноклональных антител к полной молекуле FGF-23). Забор цельной крови выполняли через 2 дня после последнего сеанса ГД перед началом очередной процедуры.
Online Inquiry
Verification code
Inquiry Basket